Sichuan Kelun Pharmacy Institute

Kelun-Biotech, a subsidiary of Sichuan Kelun Pharmaceutical, is a leading clinical-stage biotech company specializing in the development of antibody-drug conjugates (ADCs) and other novel biologics. The company has established a robust proprietary ADC platform, OptiADC, which has facilitated high-profile global partnerships, most notably a multi-program collaboration with Merck & Co. (MSD) valued at billions of dollars. Their lead candidate, sacituzumab tirumotecan (SKB264), is a TROP2-directed ADC currently in late-stage clinical trials for various solid tumors. Beyond ADCs, Kelun-Biotech maintains a diverse pipeline including monoclonal antibodies and small molecules targeting oncology and autoimmune diseases. The company is headquartered in Chengdu, China, and is listed on the Hong Kong Stock Exchange.